Alkermes (ALKS) stock forecast for 2023. Forecast tables and graphs.







6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …
Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Vanskelig å Få Refinansiering: Why Was Your Refinancing Loan Denied?

February 15, 2024 Vanskelig å Få Refinansiering: Why Was Your Refinancing Loan Denied?

At historically low interest rates, refinancing can seem tempting; but applications for refinance could be denied for various reasons. Underwriters need assurances that…

Alkermes (ALKS) stock forecast for 2023

Updated: March 25, 2024 (12:38)

Sector: Healthcare

The share price of Alkermes plc (ALKS) now

What analysts predict: $35.09
52-week High/Low: $33.71 / $22.01

50/200 Day Moving Average: $28.46 / $28.26

This figure corresponds to the Average Price over the previous 50/200 days. For Alkermes stocks, the 50-day moving average is the resistance level today.

For Alkermes stocks, the 200-day moving average is the resistance level today.

Are you interested in Alkermes plc stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Alkermes stock price in 2023. How much will one Alkermes share be worth in 2023? Is it worth taking profit / loss on ALKS stock now or waiting? What are analysts' forecasts for Alkermes stock?

We forecast Alkermes stock performance using neural networks based on historical data on ALKS stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. This corporation stock prediction results are shown below and presented as a graph, table and text information.

Alkermes plc stock forecasts are adjusted once a day based on the closing price of the previous trading day.

The minimum target price for Alkermes analysts is $35.09. Today 200 Day Moving Average is the support level (28.26 $). 50 Day Moving Average is the support level (28.46 $).




Historical and forecast chart of Alkermes plc stock

The chart below shows the historical price of Alkermes stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the ALKS stock price can be found in the table below.


Alkermes plc is an Irish biopharmaceutical company that researches, develops and markets pharmaceutical products used in a variety of therapeutic areas around the world. The company’s products include drugs for the treatment of schizophrenia, schizoaffective, depressive and bipolar disorder, alcohol and opioid addiction, aids to improve walking in adults with multiple sclerosis, and a drug for the treatment of type 2 diabetes. The company serves pharmaceutical wholesalers, specialized pharmacies and distributors.

Alkermes (ALKS) Forecast for 2023

Month Target Pes. Opt. Vol., %

Alkermes information and performance

Alkermes Address

CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, IE

Market Capitalization: 4 559 504 000 $

Market capitalization of the Alkermes plc is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ALKS shares in the company outstanding by the market price of one share.

EBITDA: 495 049 000 $

EBITDA of Alkermes is earnings before interest, income tax and depreciation of assets.

PE Ratio: 8.92

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: -1057.29

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: 3.06

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 0.239
Trailing PE: 8.92

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 10.67

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 2.499

Enterprise Value (EV) /Revenue

EV To EBITDA: 8.0

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 167076000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Alkermes price target for 2023 by month




Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.